Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation.
10.3346/jkms.2015.30.10.1416
- Author:
Yong Won CHOI
1
;
Seong Hyun JEONG
;
Mi Sun AHN
;
Hyun Woo LEE
;
Seok Yun KANG
;
Jin Hyuk CHOI
;
Joon Seong PARK
Author Information
1. Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea. jspark65@ajou.ac.kr
- Publication Type:Original Article
- Keywords:
Maintenance;
Leukemia;
Myeloid;
Acute
- MeSH:
6-Mercaptopurine/*therapeutic use;
Adolescent;
Adult;
Aged;
Antimetabolites, Antineoplastic/*therapeutic use;
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use;
Cytarabine/therapeutic use;
Disease-Free Survival;
Female;
Humans;
Idarubicin/therapeutic use;
Leukemia, Myeloid, Acute/*drug therapy/mortality;
Maintenance Chemotherapy/*methods;
Male;
Methotrexate/*therapeutic use;
Middle Aged;
Remission Induction;
Treatment Outcome;
Young Adult
- From:Journal of Korean Medical Science
2015;30(10):1416-1422
- CountryRepublic of Korea
- Language:English
-
Abstract:
For decades, maintenance chemotherapy has failed to improve the cure rate or prolong the survival of patients with acute myeloid leukemia (AML), other than those with acute promyelocytic leukemia. Immediately after the first complete remission following consolidation therapy was obtained, oral maintenance chemotherapy (daily 6-mercaptopurine and weekly methotrexate) was given and continued for two years in transplant-ineligible AML patients. Leukemia-free survival (LFS) and overall survival (OS) were studied and compared between these patients and the historical control group who did not receive maintenance therapy. Consecutive 52 transplant-ineligible AML patients were analyzed. Among these patients, 27 received oral maintenance chemotherapy. No significant difference was found in the patients' characteristics between the maintenance and the control groups. The median OS was 43 (95% CI, 19-67) and 19 (95% CI, 8-30) months in the maintenance and the control groups, respectively (P = 0.202). In the multivariate analysis, the presence of maintenance therapy was an independent prognostic factor for better OS (P = 0.021) and LFS (P = 0.024). Clinical benefit from maintenance chemotherapy was remarkable in older patients (> or = 60 yr) (P = 0.035), those with intermediate or unfavorable cytogenetics (P = 0.006), those with initial low blast count in peripheral blood (P = 0.044), and those receiving less than two cycles of consolidation therapy (P = 0.017). Maintenance oral chemotherapy as a post-remission therapy can prolong the survival of patients with AML who are not eligible for transplantation, particularly older patients, those with intermediate or unfavorable cytogenetics, those with initial low blast count, and those receiving less than two cycles of consolidation therapy.
